Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026)
Sarepta Therapeutics' quarterly Free Cash Flow came in at -$204.8 million in Q1 2026, up 67.35% year-on-year from -$122.4 million in Q1 2025, and down 260.45% quarter-over-quarter from $127.6 million in Q4 2025.
Sarepta Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$204.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 67.35% year-over-year to -$204.8 million; the trailing twelve-month figure through Mar 2026 stood at $114.9 million (up 116.52% YoY), and the FY2025 full-year result was -$307.5 million, up 10.3% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$204.8 million, down from $127.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $229.5 million in Q2 2025, with the low at -$627.1 million in Q1 2025.
- Average Free Cash Flow over 5 years is -$105.2 million, with a median of -$100.4 million recorded in 2022.
- Year-over-year, Free Cash Flow sank 218.27% in 2022 and jumped 1713.64% in 2025.
- Tracing SRPT's Free Cash Flow over 5 years: stood at -$100.4 million in 2022, then gained by 26.57% to -$73.7 million in 2023, then soared by 173.23% to $54.0 million in 2024, then surged by 136.48% to $127.6 million in 2025, then plunged by 260.45% to -$204.8 million in 2026.
- The last three Free Cash Flow figures came in at -$204.8 million (Q1 2026), $127.6 million (Q4 2025), and -$37.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | -204.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -204.76 Mn |
| Mar 31, 2026 | -204.76 Mn |
| Dec 31, 2025 | 127.62 Mn |
| Dec 31, 2025 | 127.62 Mn |
| Sep 30, 2025 | -37.52 Mn |
| Sep 30, 2025 | -37.52 Mn |
| Jun 30, 2025 | 229.54 Mn |
| Jun 30, 2025 | 229.54 Mn |
| Mar 31, 2025 | -627.09 Mn |
| Mar 31, 2025 | -627.09 Mn |
| Dec 31, 2024 | 53.96 Mn |
| Dec 31, 2024 | 53.96 Mn |
| Sep 30, 2024 | -107.96 Mn |
| Sep 30, 2024 | -107.96 Mn |
| Jun 30, 2024 | -14.23 Mn |
| Jun 30, 2024 | -14.23 Mn |
| Mar 31, 2024 | -274.52 Mn |
| Mar 31, 2024 | -274.52 Mn |
| Dec 31, 2023 | -73.70 Mn |
| Dec 31, 2023 | -73.70 Mn |
| Sep 30, 2023 | -144.38 Mn |
| Sep 30, 2023 | -144.38 Mn |
| Jun 30, 2023 | -140.14 Mn |
| Jun 30, 2023 | -140.14 Mn |
| Mar 31, 2023 | -218.88 Mn |
| Mar 31, 2023 | -218.88 Mn |
| Dec 31, 2022 | -100.36 Mn |
| Dec 31, 2022 | -100.36 Mn |
| Sep 30, 2022 | -73.20 Mn |
| Sep 30, 2022 | -73.20 Mn |
| Jun 30, 2022 | -75.89 Mn |
| Jun 30, 2022 | -75.89 Mn |
| Mar 31, 2022 | -106.73 Mn |
| Mar 31, 2022 | -106.73 Mn |
| Dec 31, 2021 | -31.53 Mn |
| Dec 31, 2021 | -31.53 Mn |
| Sep 30, 2021 | -133.57 Mn |
| Sep 30, 2021 | -133.57 Mn |
| Jun 30, 2021 | -115.04 Mn |
| Jun 30, 2021 | -115.04 Mn |
| Mar 31, 2021 | -201.52 Mn |
| Mar 31, 2021 | -201.52 Mn |
| Dec 31, 2020 | -203.15 Mn |
| Dec 31, 2020 | -203.15 Mn |
| Sep 30, 2020 | -263.49 Mn |
| Sep 30, 2020 | -263.49 Mn |
| Jun 30, 2020 | -126.77 Mn |
| Jun 30, 2020 | -126.77 Mn |
| Mar 31, 2020 | 618.67 Mn |
| Mar 31, 2020 | 618.67 Mn |
| Dec 31, 2019 | -181.05 Mn |
| Dec 31, 2019 | -181.05 Mn |
| Sep 30, 2019 | -76.86 Mn |
| Sep 30, 2019 | -76.86 Mn |
| Jun 30, 2019 | -95.69 Mn |
| Jun 30, 2019 | -95.69 Mn |
| Mar 31, 2019 | -162.50 Mn |
| Mar 31, 2019 | -162.50 Mn |
| Dec 31, 2018 | -142.62 Mn |
| Dec 31, 2018 | -142.62 Mn |
| Sep 30, 2018 | -133.41 Mn |
| Sep 30, 2018 | -133.41 Mn |
| Jun 30, 2018 | -125.95 Mn |
| Jun 30, 2018 | -125.95 Mn |
| Mar 31, 2018 | -47.83 Mn |
| Mar 31, 2018 | -47.83 Mn |
| Dec 31, 2017 | -34.96 Mn |
| Dec 31, 2017 | -34.96 Mn |
| Sep 30, 2017 | -58.67 Mn |
| Sep 30, 2017 | -58.67 Mn |
| Jun 30, 2017 | -88.02 Mn |
| Jun 30, 2017 | -88.02 Mn |
| Mar 31, 2017 | -62.35 Mn |
| Mar 31, 2017 | -62.35 Mn |
| Dec 31, 2016 | -84.15 Mn |
| Dec 31, 2016 | -84.15 Mn |
| Sep 30, 2016 | -61.46 Mn |
| Sep 30, 2016 | -61.46 Mn |
| Jun 30, 2016 | -43.70 Mn |
| Jun 30, 2016 | -43.70 Mn |
| Mar 31, 2016 | -61.86 Mn |
| Mar 31, 2016 | -61.86 Mn |
| Dec 31, 2015 | -32.36 Mn |
| Dec 31, 2015 | -32.36 Mn |
| Sep 30, 2015 | -47.46 Mn |
| Sep 30, 2015 | -47.46 Mn |
| Jun 30, 2015 | -29.17 Mn |
| Jun 30, 2015 | -29.17 Mn |
| Mar 31, 2015 | -43.88 Mn |
| Mar 31, 2015 | -43.88 Mn |
| Dec 31, 2014 | -28.59 Mn |
| Dec 31, 2014 | -28.59 Mn |
| Sep 30, 2014 | -47.79 Mn |
| Sep 30, 2014 | -47.79 Mn |
| Jun 30, 2014 | -44.02 Mn |
| Jun 30, 2014 | -44.02 Mn |
| Mar 31, 2014 | -33.59 Mn |
| Mar 31, 2014 | -33.59 Mn |
| Dec 31, 2013 | -18.43 Mn |
| Dec 31, 2013 | -18.43 Mn |
| Sep 30, 2013 | -21.21 Mn |
| Sep 30, 2013 | -21.21 Mn |
| Jun 30, 2013 | -12.43 Mn |
| Jun 30, 2013 | -12.43 Mn |
| Mar 31, 2013 | -15.00 Mn |
| Mar 31, 2013 | -15.00 Mn |
| Dec 31, 2012 | -7.16 Mn |
| Dec 31, 2012 | -7.16 Mn |
| Sep 30, 2012 | -7.77 Mn |
| Sep 30, 2012 | -7.77 Mn |
| Jun 30, 2012 | -5.82 Mn |
| Jun 30, 2012 | -5.82 Mn |
| Mar 31, 2012 | -9.06 Mn |
| Mar 31, 2012 | -9.06 Mn |
| Dec 31, 2011 | -5.85 Mn |
| Dec 31, 2011 | -5.85 Mn |
| Sep 30, 2011 | -7.82 Mn |
| Sep 30, 2011 | -7.82 Mn |
| Jun 30, 2011 | -891,000.00 |
| Jun 30, 2011 | -891,000.00 |
| Mar 31, 2011 | -10.29 Mn |
| Mar 31, 2011 | -10.29 Mn |
| Dec 31, 2010 | -2.09 Mn |
| Dec 31, 2010 | -2.09 Mn |
| Sep 30, 2010 | -3.06 Mn |
| Sep 30, 2010 | -3.06 Mn |